^
    over2years
    L105, a next generation of Bcl-2 inhibitor, overcomes Bcl-2 mutation and exhibits superior antitumor activity (AACR 2023)
    L105 showed great potency on wild type and acquisition resistance mutations of Bcl-2, excellent oral bioavailability, and superior preclinical anti-tumor activities and safety profiles. It may provide new thoughts on treatment for a wide range of Bcl-2-dependent and Venetoclax-resistant hematological cancers.
    IO biomarker
    |
    BCL2L1 (BCL2-like 1) • CASP3 (Caspase 3)
    |
    BCL2 overexpression • BCL2 mutation • BCL2 G101V
    |
    Venclexta (venetoclax) • L105